Pathologic Complete Response in Rectal Cancer: Can We Detect It? Lessons Learned From a Proposed Randomized Trial of Watch-and-Wait Treatment of Rectal Cancer

Show simple item record

dc.contributor Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.author NAHAS, Sergio Carlos FMUSP-HC
NAHAS, Caio Sergio Rizkallah FMUSP-HC
MARQUES, Carlos Frederico Sparapan FMUSP-HC
RIBEIRO JR., Ulysses FMUSP-HC
COTTI, Guilherme Cutait FMUSP-HC
IMPERIALE, Antonio Rocco FMUSP-HC
CAPARELI, Fernanda Cunha FMUSP-HC
CHEN, Andre Tsin Chih FMUSP-HC
HOFF, Paulo M. FMUSP-HC
CECCONELLO, Ivan FMUSP-HC
dc.date.issued 2016
dc.identifier.citation DISEASES OF THE COLON & RECTUM, v.59, n.4, p.255-263, 2016
dc.identifier.issn 0012-3706
dc.identifier.uri http://observatorio.fm.usp.br/handle/OPI/14230
dc.description.abstract BACKGROUND: Chemoradiotherapy has the potential to downsize and downstage tumors before surgery, decrease locoregional recurrence, and induce a complete sterilization of tumor cells for middle and low locally advanced rectal cancer. A watch-and-wait tactic has been proposed for patients with clinical complete response.(7 R8 R9 R10 R11 R12 R13 R14 R15 R16 R17 R18 R19""> 7-19) OBJECTIVE: The purpose of this study was to verify our ability to identify complete clinical response in patients with rectal cancer based on clinical and radiologic criteria. DESIGN: This was a prospective study. SETTINGS: The study was conducted at a single institution, in the setting of a watch-and-wait randomized trial. PATIENTS: Consecutive patients with stage T3 to T4N0M0 or T(any)N+M0 cancer located within 10 cm from anal verge or T2N0 within 7 cm from anal verge were included in the study. Patients were staged and restaged 8 weeks after completion of chemoradiation (5-fluorouracil, 5040 cGy) by digital examination, colonoscopy, pelvic MRI, and thorax and abdominal CT scans. MAIN OUTCOME MEASURES: Clinical and radiologic judgments of tumor response were compared with pathologic response of patients treated by total mesorectal excision or clinical follow-up of patients selected for nonoperative treatment. RESULTS: A total of 118 patients were treated. Six patients were considered clinic complete responders (2 randomly assigned for surgery (1 ypT0N0 and 1 ypT2N0) and 4 patients randomly assigned for observation (3 sustained clinic complete response and 1 had tumor regrowth)). The 112 clinic incomplete responders underwent total mesorectal excision, and 18 revealed pathologic complete response. These 18 patients were not considered complete responders at restaging because they presented at least 1 of the following conditions: mucosal ulceration and/or deformity and/or substenosis of rectal lumen at digital rectal examination and colonoscopy (n = 16), ymrT1 to T4 (n = 16), ymrN+ (n = 2), involvement of circumferential resection margin on MRI (n = 3), extramural vascular invasion on MRI (n = 4), MRI tumor response grade 2 to 4 (n = 15), and pelvic side wall lymph node involvement on MRI (n = 1). Sensitivity for identification of ypT0N0 or sustained clinic complete response was 18.2%. LIMITATIONS: This study has a short follow-up and small sample size. Radiologists who reviewed the restaging examination were not blinded to the pretreatment stage. Only 1 radiologist read the images of each patient. CONCLUSIONS: Evaluation of clinic complete response according to current adopted criteria has low sensitivity because pathologic complete response more frequently presented as clinic incomplete response (see Video, Supplemental Digital Content 1, [GRAPHICS] ).
dc.language.iso eng
dc.publisher LIPPINCOTT WILLIAMS & WILKINS
dc.relation.ispartof Diseases of the Colon & Rectum
dc.rights restrictedAccess
dc.subject Watchful waiting; Rectal tumor; Rectal neoplasms; Neoadjuvant treatment; Rectal cancer
dc.subject.other neoadjuvant chemoradiation therapy; complete clinical-response; preoperative chemoradiation; nonoperative management; see policy; chemoradiotherapy; survival; radiotherapy; carcinoma; tumor
dc.title Pathologic Complete Response in Rectal Cancer: Can We Detect It? Lessons Learned From a Proposed Randomized Trial of Watch-and-Wait Treatment of Rectal Cancer
dc.type article
dc.rights.holder Copyright LIPPINCOTT WILLIAMS & WILKINS
dc.description.group LIM/24
dc.description.group LIM/35
dc.description.group LIM/37
dc.identifier.doi 10.1097/DCR.0000000000000558
dc.identifier.pmid 26953983
dc.type.category original article
dc.type.version publishedVersion
hcfmusp.author NAHAS, Sergio Carlos:HC:ICHC
hcfmusp.author NAHAS, Caio Sergio Rizkallah:HC:ICESP
hcfmusp.author MARQUES, Carlos Frederico Sparapan:HC:ICESP
hcfmusp.author RIBEIRO JR., Ulysses:FM:MGT
hcfmusp.author COTTI, Guilherme Cutait:HC:ICESP
hcfmusp.author IMPERIALE, Antonio Rocco:HC:ICESP
hcfmusp.author CAPARELI, Fernanda Cunha:HC:ICESP
hcfmusp.author CHEN, Andre Tsin Chih:HC:ICESP
hcfmusp.author HOFF, Paulo M.:FM:MDR
hcfmusp.author CECCONELLO, Ivan:FM:MGT
hcfmusp.origem.id WOS:000372150100003
hcfmusp.origem.id 2-s2.0-84962611024
hcfmusp.publisher.city PHILADELPHIA
hcfmusp.publisher.country USA
hcfmusp.relation.reference · Maas M, 2011, J CLIN ONCOL, V29, P4633, DOI 10.1200/JCO.2011.37.7176
· Habr-Gama A, 2004, ANN SURG, V240, P711, DOI 10.1097/01.sla.0000141194.27992.32
· Glynne-Jones R, 2012, BRIT J SURG, V99, P897, DOI 10.1002/bjs.8732
· Nakagawa WT, 2002, ANN SURG ONCOL, V9, P568, DOI 10.1245/aso.2002.9.6.568
· Guillem JG, 2005, J CLIN ONCOL, V23, P3475, DOI 10.1200/JCO.2005.06.114
· Patel UB, 2011, J CLIN ONCOL, V29, P3753, DOI 10.1200/JCO.2011.34.9068
· Habr-Gama A, 2006, J GASTROINTEST SURG, V10, P1319, DOI 10.1016/j.gassur.2006.09.005
· Allen SD, 2007, AM J ROENTGENOL, V188, P442, DOI 10.2214/AJR.05.1967
· Smith JD, 2012, ANN SURG, V256, P965, DOI 10.1097/SLA.0b013e3182759f1c
· Habr-Gama A, 2013, DIS COLON RECTUM, V56, P1109, DOI 10.1097/DCR.0b013e3182a25c4e
· Chen CC, 2005, DIS COLON RECTUM, V48, P722, DOI 10.1007/s10350-004-0851-1
· Kapiteijn E, 2001, NEW ENGL J MED, V345, P638, DOI 10.1056/NEJMoa010580
· Habr-Gama A, 2010, DIS COLON RECTUM, V53, P1692, DOI 10.1007/DCR.0b013e3181f42b89
· Smith FM, 2006, EJSO, V32, P55, DOI 10.1016/j.ejso.2005.09.010
· Hiotis SP, 2002, J AM COLL SURGEONS, V194, P131, DOI 10.1016/S1072-7515(01)01159-0
· Mignanelli ED, 2010, DIS COLON RECTUM, V53, P251, DOI 10.1007/DCR.0b013e3181bcd3cc
· Pahlman L, 1997, NEW ENGL J MED, V336, P980
· Sauer R, 2004, NEW ENGL J MED, V351, P1731, DOI 10.1056/NEJMoa040694
· Smith FM, 2014, DIS COLON RECTUM, V57, P311, DOI 10.1097/DCR.0b013e3182a84eba
· Dalton RSJ, 2012, COLORECTAL DIS, V14, P567, DOI 10.1111/j.1463-1318.2011.02752.x
· Hughes R, 2010, ACTA ONCOL, V49, P378, DOI 10.3109/02841860903483692
· Rossi BM, 1998, ANN SURG ONCOL, V5, P113, DOI 10.1007/BF02303843
· Habr-Gama A, 1998, DIS COLON RECTUM, V41, P1087, DOI 10.1007/BF02239429
· Beddy D, 2008, ANN SURG ONCOL, V15, P3471, DOI 10.1245/s10434-008-0149-y
· Lim L, 2007, DIS COLON RECTUM, V50, P2032, DOI 10.1007/s10350-007-9062-x
· Kuo LJ, 2005, DIS COLON RECTUM, V48, P23, DOI 10.1007/s10350-004-0787-5
· Yu SK, 2011, J CLIN ONCOL S4, V29
dc.description.index MEDLINE
dc.identifier.eissn 1530-0358
hcfmusp.citation.scopus 47
hcfmusp.scopus.lastupdate 2021-08-27


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search DSpace



Browse

My Account

Statistics